NovaBay Pharmaceuticals (NYSEAMERICAN:NBY) Shares Gap Up - Time to Buy?

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY - Get Free Report) gapped up prior to trading on Friday . The stock had previously closed at $2.95, but opened at $3.10. NovaBay Pharmaceuticals shares last traded at $4.2880, with a volume of 1,542,718 shares traded.NovaBay Pharmaceuticals Trading Up 84.6%The stock has a 50 day moving average of $1.37 and a 200-day moving average of $1.22. The company has a market capitalization of $686.25 million, a P/E ratio of -0.57 and a beta of 0.57. NovaBay Pharmaceuticals Dividend AnnouncementThe business also recently announced a dividend, which was paid on Monday, September 29th. Stockholders of record on Wednesday, October 1st were issued a $0.80 dividend. This represents a dividend yield of 3,791.0%. The ex-dividend date of this dividend was Tuesday, September 30th. Institutional Trading of NovaBay PharmaceuticalsA number of institutional investors and hedge funds have recently bought and sold shares of NBY. C2C Wealth Management LLC boosted its holdings in shares of NovaBay Pharmaceuticals by 78.2% during the 2nd quarter. C2C Wealth Management LLC now owns 98,000 shares of the biopharmaceutical company's stock valued at $57,000 after purchasing an additional 43,000 shares during the last quarter. Apollon Wealth Management LLC bought a new stake in shares of NovaBay Pharmaceuticals in the third quarter worth about $35,000. Finally, Ground Swell Capital LLC purchased a new stake in shares of NovaBay Pharmaceuticals in the third quarter worth about $25,000. 23.25% of the stock is currently owned by institutional investors. About NovaBay Pharmaceuticals (Get Free Report)NovaBay Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, non-antibiotic anti-infective products designed to regulate the innate immune response. Leveraging its proprietary Aganocide® Technology, the company's synthetic antimicrobial compounds target and neutralize pathogens without contributing to antibiotic resistance. NovaBay's research and development efforts concentrate on ophthalmic, dermatological and wound care applications, aiming to address unmet needs in infection control and inflammation management. The company's primary commercial products include Avenova®, an eyelid and lash cleaning solution indicated for managing chronic blepharitis and meibomian gland dysfunction, and NeutroPhase®, a pure hypochlorous acid wound and skin cleanser used in acute and chronic wound irrigation.Recommended StoriesFive stocks we like better than NovaBay Pharmaceuticals3 Natural Gas Stocks That Offer Great Dividend YieldsIs the AI Boom a Bubble? These 2 Dividend Stocks Say NoMost Volatile Stocks, What Investors Need to Know4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and MoreInsider Selling Explained: Can it Inform Your Investing Choices?META Rises Amid Tech Decline, Trump's AI Order Praised By AnalystThis instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.Should You Invest $1,000 in NovaBay Pharmaceuticals Right Now?Before you consider NovaBay Pharmaceuticals, you'll want to hear this.MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and NovaBay Pharmaceuticals wasn't on the list.While NovaBay Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.View The Five Stocks Here